Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 1/20 | 0.76 |
| ▸ | HPRT1 | P00492 | 7/20 | 0.69 |
| ▸ | PNP | P00491 | 11/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | EDNRA | P25101 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | HBB | P68871 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8196749 | 0.96 | TK1 (0.78) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL9806969 | 0.91 | TK1 (0.71) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL20012346 | 0.90 | TK1 (0.74) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL29286376 | 0.90 | TK1 (0.76) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL3793003 | 0.89 | TK1 (0.76) | TK1HPRT1PNP | |
| SCHEMBL3836263 | 0.87 | TK1 (0.92) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL6272731 | 0.87 | TK1 (0.74) | TK1HPRT1PNP | |
| SCHEMBL27506929 | 0.87 | TK1 (0.74) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL571645 | 0.86 | TK1 (1.00) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL8522271 | 0.86 | TK1 (0.76) | TK1HPRT1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922859-B1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | UNIV CORK (IE) | 2021-05-05 | — | — | EP | claimed |
| US-9822137-B2 | Phosphonucleosides useful in the treatment of viral disorders | UNIVERSITY COLLEGE CORK (IE) | 2017-11-21 | — | — | US | claimed |
| US-20150291640-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-10-15 | — | — | US | claimed |
| EP-2922859-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | University College Cork (IE) | 2015-09-30 | — | — | EP | claimed |
| WO-2014079903-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | UNIVERSITY COLLEGE CORK (IE) | 2014-05-30 | — | — | WO | claimed |
| EP-2922859-B1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | UNIV CORK (IE) | 2021-05-05 | — | — | EP | disclosed |
| CN-111050806-A | Oligonucleotide compositions and methods of use thereof | 波涛生命科学有限公司 | 2020-04-21 | — | — | CN | disclosed |
| US-10167302-B2 | Phosphonate nucleosides useful in the treatment of viral diseases | UNIVERSITY COLLEGE CORK (IE) | 2019-01-01 | — | — | US | disclosed |
| US-9822137-B2 | Phosphonucleosides useful in the treatment of viral disorders | UNIVERSITY COLLEGE CORK (IE) | 2017-11-21 | — | — | US | disclosed |
| US-20170218001-A1 | PHOSPHONATE NUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2017-08-03 | — | — | US | disclosed |
| EP-3145939-A1 | PHOSPHONATE NUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISEASES | University College Cork (IE) | 2017-03-29 | — | — | EP | disclosed |
| WO-2015177351-A1 | PHOSPHONATE NUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISEASES | UNIVERSITY COLLEGE CORK (IE) | 2015-11-26 | — | — | WO | disclosed |
| US-20150291640-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-10-15 | — | — | US | disclosed |
| EP-2922859-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | University College Cork (IE) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014079903-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | UNIVERSITY COLLEGE CORK (IE) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167302-B2 | Phosphonate nucleosides useful in the treatment of viral diseases | NR3C1, NR2E3, NR2E1 | TK1 106/4885HPRT1 35/4885PNP 98/4885 |
| US-20170218001-A1 | PHOSPHONATE NUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISEASES | NR3C1, NR2E3, NR2E1 | TK1 106/4885HPRT1 35/4885PNP 98/4885 |
| US-20150291640-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | ENTPD5, PNP, MTAP | TK1 87/4885HPRT1 66/4885PNP 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.